Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Abeona Therapeutics stock

Learn how to easily invest in Abeona Therapeutics stock.

Abeona Therapeutics Inc is a biotechnology business based in the US. Abeona Therapeutics shares (ABEO) are listed on the NASDAQ and all prices are listed in US Dollars. Abeona Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Abeona Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABEO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Abeona Therapeutics stock price (NASDAQ: ABEO)

Use our graph to track the performance of ABEO stocks over time.

Abeona Therapeutics shares at a glance

Information last updated 2022-07-01.
Latest market close$0.19
52-week range$0.13 - $1.56
50-day moving average $0.18
200-day moving average $0.45
Wall St. target price$2.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.81

Buy Abeona Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Abeona Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abeona Therapeutics price performance over time

Historical closes compared with the close of $0.19 from 2022-07-01

1 week (2022-06-28) 3.15%
1 month (2022-06-01) 22.50%
3 months (2022-04-05) -44.30%
6 months (2022-01-05) -40.68%
1 year (2021-07-02) -87.74%
2 years (2020-07-02) -93.33%
3 years (2019-07-05) 4.56
5 years (2017-07-05) 7.3

Abeona Therapeutics financials

Revenue TTM $3.3 million
Gross profit TTM $-299,000
Return on assets TTM -36.37%
Return on equity TTM -142.61%
Profit margin 0%
Book value $0.21
Market capitalisation $30.6 million

TTM: trailing 12 months

Abeona Therapeutics share dividends

We're not expecting Abeona Therapeutics to pay a dividend over the next 12 months.

Have Abeona Therapeutics's shares ever split?

Abeona Therapeutics's shares were split on a 1:50 basis on 23 October 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Abeona Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Abeona Therapeutics shares which in turn could have impacted Abeona Therapeutics's share price.

Abeona Therapeutics share price volatility

Over the last 12 months, Abeona Therapeutics's shares have ranged in value from as little as $0.13 up to $1.56. A popular way to gauge a stock's volatility is its "beta".

ABEO.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abeona Therapeutics's is 1.5. This would suggest that Abeona Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Abeona Therapeutics overview

Abeona Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc.

Frequently asked questions

What percentage of Abeona Therapeutics is owned by insiders or institutions?
Currently 10.263% of Abeona Therapeutics shares are held by insiders and 21.888% by institutions.
How many people work for Abeona Therapeutics?
Latest data suggests 90 work at Abeona Therapeutics.
When does the fiscal year end for Abeona Therapeutics?
Abeona Therapeutics's fiscal year ends in December.
Where is Abeona Therapeutics based?
Abeona Therapeutics's address is: 1330 Avenue of the Americas, New York, NY, United States, 10019
What is Abeona Therapeutics's ISIN number?
Abeona Therapeutics's international securities identification number is: US00289Y1073
What is Abeona Therapeutics's CUSIP number?
Abeona Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00289Y107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site